Purple Biotech (PPBT) ehemals KTOV (Mkap $16 M) ( Cash $17 M) US Zulassungsantrag diesen Quartal (Seite 21)
eröffnet am 18.07.17 17:14:19 von
neuester Beitrag 04.06.24 19:51:10 von
neuester Beitrag 04.06.24 19:51:10 von
Beiträge: 1.798
ID: 1.257.452
ID: 1.257.452
Aufrufe heute: 0
Gesamt: 149.452
Gesamt: 149.452
Aktive User: 0
ISIN: US74638P1093 · WKN: A2QLTP · Symbol: 1YI1
0,5650
EUR
0,00 %
0,0000 EUR
Letzter Kurs 14.06.24 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
01.06.24 · globenewswire  |
21.05.24 · globenewswire |
25.04.24 · globenewswire |
28.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,8000 | +2.566,67 | |
| 5,9000 | +83,23 | |
| 0,6350 | +50,47 | |
| 3,3000 | +44,74 | |
| 1,7880 | +39,47 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6800 | -23,60 | |
| 2,7900 | -24,80 | |
| 1,0100 | -26,81 | |
| 9,5300 | -34,00 | |
| 1,0200 | -34,19 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 68.280.781 von RemoteTrader am 23.05.21 14:33:53keine ahnung ob wir das schon hatten
Purple Biotech to Present at the Jefferies Virtual Healthcare Conference
Date: Friday, June 4, 2021
https://finance.yahoo.com/news/purple-biotech-present-jeffer…
Purple Biotech to Present at the Jefferies Virtual Healthcare Conference
Date: Friday, June 4, 2021
https://finance.yahoo.com/news/purple-biotech-present-jeffer…
Antwort auf Beitrag Nr.: 68.280.223 von Sven_Bonn am 23.05.21 12:50:11Ich bin nicht böse, wenn es einen Runup geben sollte. Bin immer noch stark engagiert, aber VTGN und PRVB haben ebenfalls großes Potenzial. Fühle mich mit der neuen Portfolio-Gewichtung wohler...
Antwort auf Beitrag Nr.: 68.276.818 von RemoteTrader am 22.05.21 16:23:34Hi RemoteTrader,
hoffentlich bereust Du die Reduzierung nicht...
So langsam kommt ja hier Bewegung rein..
Wenn die Nachrichten am 4.6. gut sind, sehen wir hoffentlich 2-stellige Kurse...
Lieben Gruß
Sven
hoffentlich bereust Du die Reduzierung nicht...
So langsam kommt ja hier Bewegung rein..
Wenn die Nachrichten am 4.6. gut sind, sehen wir hoffentlich 2-stellige Kurse...
Lieben Gruß
Sven
Antwort auf Beitrag Nr.: 68.253.841 von Sven_Bonn am 20.05.21 13:06:25Daumen drücken!
Hab mein PPBT Exposure etwas reduziert, bin aber weiterhin long...
Auf geht's, das Price Target liegt bei 25$!
Hab mein PPBT Exposure etwas reduziert, bin aber weiterhin long...
Auf geht's, das Price Target liegt bei 25$!
okay.. also der 4. Juni !!!
https://quantisnow.com/insight/779887
Initial Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Solid Tumors and Head and Neck Cancer to be Highlighted
REHOVOT, Israel, May 20, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, announced today that it will present new data from the ongoing Phase 1/2 clinical trial of NT219 on Friday, June 4, 2021, at the 2021 ASCO Annual Meeting, which will be held virtually from June 4-8.
NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The Phase 1/2 trial is evaluating NT219 as monotherapy treatment of advanced solid tumors, as well as in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the treatment of recurrent and/or metastatic solid tumors and head and neck cancer or colorectal adenocarcinoma.
"We are excited to present interim data from our ongoing Phase 1/2 clinical trial of NT219 as monotherapy for the treatment of solid tumors that has the potential to help people living with hard-to-treat cancers," said Bertrand Liang, M.D., Ph.D., Chief Medical Officer of Purple Biotech. "We are excited to have clinical data for our NT219 program and we continue to expect the availability of further top-line data from the first part of this study in the second half of this year."
Details of the presentation are as follows:
Title: A Phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with Cetuximab in Adults with Advanced Solid Tumors and Head and Neck Cancer.
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Location: ASCO Meeting Library
https://quantisnow.com/insight/779887
Initial Data from Ongoing Phase 1/2 Clinical Trial of NT219 in Adults with Advanced Solid Tumors and Head and Neck Cancer to be Highlighted
REHOVOT, Israel, May 20, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, announced today that it will present new data from the ongoing Phase 1/2 clinical trial of NT219 on Friday, June 4, 2021, at the 2021 ASCO Annual Meeting, which will be held virtually from June 4-8.
NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The Phase 1/2 trial is evaluating NT219 as monotherapy treatment of advanced solid tumors, as well as in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the treatment of recurrent and/or metastatic solid tumors and head and neck cancer or colorectal adenocarcinoma.
"We are excited to present interim data from our ongoing Phase 1/2 clinical trial of NT219 as monotherapy for the treatment of solid tumors that has the potential to help people living with hard-to-treat cancers," said Bertrand Liang, M.D., Ph.D., Chief Medical Officer of Purple Biotech. "We are excited to have clinical data for our NT219 program and we continue to expect the availability of further top-line data from the first part of this study in the second half of this year."
Details of the presentation are as follows:
Title: A Phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with Cetuximab in Adults with Advanced Solid Tumors and Head and Neck Cancer.
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Location: ASCO Meeting Library
Trading Spotlight
News:
https://www.globenewswire.com/news-release/2021/05/19/223233…
Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors
May 19, 2021 07:00 ET | Source: Purple Biotech Ltd.
...
REHOVOT, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Suzana Nahum-Zilberberg, a seasoned biopharmaceutical Industry executive, to its Board of Directors.
“We are excited to welcome Suzana to our Board of Directors,” said Dr. Eric Rowinsky, Chairman of the Board of Purple Biotech. “Ms. Nahum-Zilberberg has extensive experience in senior leadership positions at several leading biopharmaceutical companies. As we continue to expeditiously advance CM24 and NT219, our promising anti-cancer clinical product candidates, we look forward to leveraging Suzana’s operational expertise in order to further advance our missions of developing impactful therapeutics for cancer patients and generating sustainable shareholder value.”
“I am delighted to join the Board of Directors of a company as innovative as Purple Biotech,” said Ms. Nahum-Zilberberg. “I welcome the opportunity to work with the other members of the Board and the Company's experienced management team to continue the development of Purple Biotech’s promising clinical pipeline and support its growth for the overall business.
Ms. Nahum-Zilberberg currently serves as Vice Chairman of the Board of BioLight Life Science, which is traded on the Tel Aviv Stock Exchange, and from 2011 to 2020 served as the CEO of BioLight. Ms. Nahum-Zilberberg also serves as a director at Human Xtention Ltd. and Nextferm Technologies Ltd., both of which are traded on the Tel Aviv Stock Exchange, and a number of private companies. Prior to joining BioLight, Ms. Nahum-Zilberberg held a number of leadership positions at Teva Pharmaceuticals Industries, including Vice President of Asia and Pacific and Director in the office of the President and CEO.
Ms. Nahum-Zilberberg holds a B.A. degree in accounting and economics and a M.B.A. degree, both from Tel Aviv University, a Certified Director degree from Tel Aviv University, and studied at the INSEAD Asian International Executive Program. She is a certified public accountant.
Purple Biotech's Board of Directors now includes eight members, six of whom are independent. Ms. Nahum-Zilberberg will serve as a member of the third class of the Board of Directors until the annual general meeting of shareholders to be held in 2021, at which time she may stand for reelection.
About Purple Biotech
Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies by overcoming tumor immune evasion and drug resistance. The Company's oncology pipeline includes NT219 and CM24. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The Company is currently advancing NT219 as a monotherapy treatment of solid tumors, followed by a dose escalation of NT219 in combination with cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN) or colorectal adenocarcinoma in a phase 1/2 study, and an expansion phase of NT219 at its recommended phase 2 level in combination with cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in selected cancer indications in a phase 1b study followed by a phase 2 for the treatment of non-small cell lung cancer and pancreatic cancer. The Company has entered into a clinical collaboration agreement, as amended, with Bristol Myers Squibb for the planned phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab (Opdivo®) in patients with non-small cell lung cancer and in combination with nivolumab in addition to nab-paclitaxel (ABRAXANE®) in patients with pancreatic cancer. The Company is also the owner of Consensi®, an FDA-approved fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension that was approved by the FDA for marketing in the U.S. Consensi® is being sold in the U.S. by Burke Therapeutics, the marketing partner of the Company's U.S. distributor, Coeptis Pharmaceuticals. The Company has also partnered to commercialize Consensi in China and South Korea. The Company corporate headquarters are located in Rehovot, Israel. For more information, please visit https://www.purple-biotech.com.
Forward-Looking Statements and Safe Harbor Statement
Certain statements in this press release that are forward-looking and not statements of historical fact are forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for NT219 and CM24; the process by which early stage therapeutic candidates such as NT219 and CM24 could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2020 and in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, https://www.sec.gov.
Company Contact:
Gil Efron
Deputy CEO & Chief Financial Officer
IR@kitovpharma.com +972-3-933-3121 ext. #105
https://www.globenewswire.com/news-release/2021/05/19/223233…
Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors
May 19, 2021 07:00 ET | Source: Purple Biotech Ltd.
...
REHOVOT, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" ", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Suzana Nahum-Zilberberg, a seasoned biopharmaceutical Industry executive, to its Board of Directors.
“We are excited to welcome Suzana to our Board of Directors,” said Dr. Eric Rowinsky, Chairman of the Board of Purple Biotech. “Ms. Nahum-Zilberberg has extensive experience in senior leadership positions at several leading biopharmaceutical companies. As we continue to expeditiously advance CM24 and NT219, our promising anti-cancer clinical product candidates, we look forward to leveraging Suzana’s operational expertise in order to further advance our missions of developing impactful therapeutics for cancer patients and generating sustainable shareholder value.”
“I am delighted to join the Board of Directors of a company as innovative as Purple Biotech,” said Ms. Nahum-Zilberberg. “I welcome the opportunity to work with the other members of the Board and the Company's experienced management team to continue the development of Purple Biotech’s promising clinical pipeline and support its growth for the overall business.
Ms. Nahum-Zilberberg currently serves as Vice Chairman of the Board of BioLight Life Science, which is traded on the Tel Aviv Stock Exchange, and from 2011 to 2020 served as the CEO of BioLight. Ms. Nahum-Zilberberg also serves as a director at Human Xtention Ltd. and Nextferm Technologies Ltd., both of which are traded on the Tel Aviv Stock Exchange, and a number of private companies. Prior to joining BioLight, Ms. Nahum-Zilberberg held a number of leadership positions at Teva Pharmaceuticals Industries, including Vice President of Asia and Pacific and Director in the office of the President and CEO.
Ms. Nahum-Zilberberg holds a B.A. degree in accounting and economics and a M.B.A. degree, both from Tel Aviv University, a Certified Director degree from Tel Aviv University, and studied at the INSEAD Asian International Executive Program. She is a certified public accountant.
Purple Biotech's Board of Directors now includes eight members, six of whom are independent. Ms. Nahum-Zilberberg will serve as a member of the third class of the Board of Directors until the annual general meeting of shareholders to be held in 2021, at which time she may stand for reelection.
About Purple Biotech
Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies by overcoming tumor immune evasion and drug resistance. The Company's oncology pipeline includes NT219 and CM24. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The Company is currently advancing NT219 as a monotherapy treatment of solid tumors, followed by a dose escalation of NT219 in combination with cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer (SCCHN) or colorectal adenocarcinoma in a phase 1/2 study, and an expansion phase of NT219 at its recommended phase 2 level in combination with cetuximab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in selected cancer indications in a phase 1b study followed by a phase 2 for the treatment of non-small cell lung cancer and pancreatic cancer. The Company has entered into a clinical collaboration agreement, as amended, with Bristol Myers Squibb for the planned phase 1/2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab (Opdivo®) in patients with non-small cell lung cancer and in combination with nivolumab in addition to nab-paclitaxel (ABRAXANE®) in patients with pancreatic cancer. The Company is also the owner of Consensi®, an FDA-approved fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension that was approved by the FDA for marketing in the U.S. Consensi® is being sold in the U.S. by Burke Therapeutics, the marketing partner of the Company's U.S. distributor, Coeptis Pharmaceuticals. The Company has also partnered to commercialize Consensi in China and South Korea. The Company corporate headquarters are located in Rehovot, Israel. For more information, please visit https://www.purple-biotech.com.
Forward-Looking Statements and Safe Harbor Statement
Certain statements in this press release that are forward-looking and not statements of historical fact are forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and objectives of management for future operations; product development for NT219 and CM24; the process by which early stage therapeutic candidates such as NT219 and CM24 could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2020 and in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, https://www.sec.gov.
Company Contact:
Gil Efron
Deputy CEO & Chief Financial Officer
IR@kitovpharma.com +972-3-933-3121 ext. #105
Antwort auf Beitrag Nr.: 68.079.872 von Sven_Bonn am 06.05.21 11:54:13Das ist halt immer noch Roulette. Die Gerichtsverfahren zu NT219 und Consensi belasten... bin immer noch überzeugt, aber so langsam mach ich mir Gedanken, ob ich nicht in PRVB und VTGN umschichte. Beide ebenfalls riskant, aber viel transparenter und ready for liftoff. Bei PPBT kann es noch Jahre dauern... Readouts in der 2. Jahreshälfte werden jedenfalls wichtig. So lange halte ich hoffentlich noch durch...
Antwort auf Beitrag Nr.: 68.078.864 von RemoteTrader am 06.05.21 11:09:27
Hi RemoteTrader,
tja.. momentan ist unser PPBT leider immer noch Spielball der Shorts...
Generell hat sich an meiner Einschätzung aber KEINESFALLS entwas geändert, habe die Kurse unter 4 USD immer wieder zum Nachkauf genutzt und werde dies auch weiter tun.
Alle letzten bekanntgmeachten Ergebnisse waren voll und ganz im soll und es hat sich gezeigt, dass CM24 keinerlei schwerwiegende Nebenwirkungen hat und Studien ausgeweitet werden:
https://seekingalpha.com/news/3685083-dosing-underway-in-pur…
An dieser Stelle kann ich Euch den User "Flipys" von Stocktwits: https://stocktwits.com/flipsy näherbringen, er hat einen sehr fachlichen Hintergrund.
Hier einer seiner neusten interessanten Beiträge..
Top-line data for part A (NT219 monotherapy) expected 2H 2021. That's a wide window. If they were being conservative, they were planning for some delays due to toxicity. Since they are on schedule ("proceeding with enrollment as planned"... no delays?), maybe it will be in the 3rd quarter?
If they don't encounter any meaningful toxicity, then I imagine they will add some additional patients at the highest dose level 50 mg/kg. They are following 3+3 design so if there is low toxicity, they won't have more than 15 people when they finish the 5th dose level, unless they add additional people just to get more data (it says 18 to 30 people...).
Totally speculative timeline, 1 week between groups:
March 2 - start level 2
April 2 - end level 2
April 9 - start level 3
May 9 - end level 3
May 16 - start level 4
June 16 - end level 4
June 23 - start level 5
July 23 - end level 5
July 30 - start 3 additional patients for level 5
Sept 1 - finish extra patients
PR in late Q3, or Q4
Wenn es etwas substanziell Neues gibt, melde ich mich.
Lieben Gruß
Sven
Hi RemoteTrader,
tja.. momentan ist unser PPBT leider immer noch Spielball der Shorts...
Generell hat sich an meiner Einschätzung aber KEINESFALLS entwas geändert, habe die Kurse unter 4 USD immer wieder zum Nachkauf genutzt und werde dies auch weiter tun.
Alle letzten bekanntgmeachten Ergebnisse waren voll und ganz im soll und es hat sich gezeigt, dass CM24 keinerlei schwerwiegende Nebenwirkungen hat und Studien ausgeweitet werden:
https://seekingalpha.com/news/3685083-dosing-underway-in-pur…
An dieser Stelle kann ich Euch den User "Flipys" von Stocktwits: https://stocktwits.com/flipsy näherbringen, er hat einen sehr fachlichen Hintergrund.
Hier einer seiner neusten interessanten Beiträge..
Top-line data for part A (NT219 monotherapy) expected 2H 2021. That's a wide window. If they were being conservative, they were planning for some delays due to toxicity. Since they are on schedule ("proceeding with enrollment as planned"... no delays?), maybe it will be in the 3rd quarter?
If they don't encounter any meaningful toxicity, then I imagine they will add some additional patients at the highest dose level 50 mg/kg. They are following 3+3 design so if there is low toxicity, they won't have more than 15 people when they finish the 5th dose level, unless they add additional people just to get more data (it says 18 to 30 people...).
Totally speculative timeline, 1 week between groups:
March 2 - start level 2
April 2 - end level 2
April 9 - start level 3
May 9 - end level 3
May 16 - start level 4
June 16 - end level 4
June 23 - start level 5
July 23 - end level 5
July 30 - start 3 additional patients for level 5
Sept 1 - finish extra patients
PR in late Q3, or Q4
Wenn es etwas substanziell Neues gibt, melde ich mich.
Lieben Gruß
Sven
Sven, Du solltest wirklich mal wieder was zur Lage der Nation schreiben. Ich hoffe auf die Readouts in 2H. Hoffen ist aber nicht wissen! 😉
Antwort auf Beitrag Nr.: 67.927.139 von spoi am 23.04.21 14:04:03"Buy the rumour - sell the news"... Das scheint bis heute passiert zu sein. Die News ist m.E. aber sehr positiv und kein Pump, so dass ich weiteres Kurspotenzial sehe. Jederzeit kann noch News zu NT219 kommen und Consensi werden sie auch noch versilbern. Denkt daran: Kursziel 25 US$! Stay long!
Durchsuchen
